Non-Statin Therapies for Lipid Management
Susan Halli-Demeter, RN, DNP, CLS reviews the benefits of non-statin, LDL-C-lowering therapies for patients with very high-risk atherosclerotic cardiovascular disease (ASCVD) and severe hypercholesterolemia.
Read More2021 Pharmacology Sessions
Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and RNs in the cardiology and primary care settings. This annual pharmacology CE program was designed to meet the clinical practice and recertification needs of these clinicians. This 2021 curriculum includes a comprehensive approach to pharmacology in: The…
Read MoreInflammation and Cardiovascular Disease: Understanding the Relationship
In this course, Donna Arnett, PhD, MSPH discusses inflammation and chronic inflammatory disease in the context of atherosclerosis. She describes inflammation as a process that links lipids to ASCVD and covers the interconnections between diet, genetics, and physical activity.
Read MoreLipid Management in 2019: Putting Evidence-Based Guidelines into Practice
Dr. Lynne Braun, nurse practitioner and clinical lipid specialist, reviews the latest update of the National Cholesterol Guideline. She addresses the Guideline’s top ten recommendations and their implications for clinical practice. The course covers the pharmacological and non-pharmacologic strategies for managing elevated LDL-C and triglycerides.
Read MoreTreating High-Risk Patients with Non-Statin Therapy for LDL-C Lowering: Optimizing Clinical Outcomes
Learn how non-statin therapies such as ezetimibe and PCSK9 inhibitors have demonstrated benefits in lowering LDL-C and reducing the risk of major adverse cardiovascular events in high-risk patients.
Read MoreThe 2019 Guideline for Primary Prevention of Cardiovascular Disease
Guideline writing panel member and former PCNA President, Dr. Cheryl Dennison-Himmelfarb provides a timely discussion of the 2019 Guideline for Primary Prevention of CVD with a focus on the role of nurses in applying the Guidelines to clinical practice. This Guideline integrates recent cholesterol, hypertension, and physical activity guidelines and addresses aspirin in primary prevention.
Read MoreCase Studies in Cardiovascular Risk Reduction with Non-statin Therapies: Rapid Fire Roundtable
In this rapid-fire roundtable session, Clinical Lipid Specialists Joyce Ross, MSN, CRNP and Dr. Lynne Braun PhD, CNP discuss PCSK9 Inhibitors in practice, including the latest data from CV outcomes studies. They demonstrate how these trials will impact practice through dynamic case studies, including a patient’s with diabetic dyslipidemia, ASCVD, and familial hypercholesterolemia.
Read More